Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults - PubMed (original) (raw)
Clinical Trial
. 2012 Oct;19(10):1651-60.
doi: 10.1128/CVI.00258-12. Epub 2012 Aug 22.
Affiliations
- PMID: 22914365
- PMCID: PMC3485893
- DOI: 10.1128/CVI.00258-12
Clinical Trial
Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults
M Wecker et al. Clin Vaccine Immunol. 2012 Oct.
Abstract
On the basis of positive preclinical data, we evaluated the safety and immunogenicity of an alphavirus replicon HIV-1 subtype C gag vaccine (AVX101), expressing a nonmyristoylated form of Gag, in two double-blind, randomized, placebo-controlled clinical trials in healthy HIV-1-uninfected adults. Escalating doses of AVX101 or placebo were administered subcutaneously to participants in the United States and Southern Africa. Because of vaccine stability issues, the first trial was halted prior to completion of all dose levels and a second trial was implemented. The second trial was also stopped prematurely due to documentation issues with the contract manufacturer. Safety and immunogenicity were evaluated through assessments of reactogenicity, reports of adverse events, and assessment of replication-competent and Venezuelan equine encephalitis (VEE) viremia. Immunogenicity was measured using the following assays: enzyme-linked immunosorbent assay (ELISA), chromium 51 ((51)Cr)-release cytotoxic T lymphocyte (CTL), gamma interferon (IFN-γ) ELISpot, intracellular cytokine staining (ICS), and lymphoproliferation assay (LPA). Anti-vector antibodies were also measured. AVX101 was well tolerated and exhibited only modest local reactogenicity. There were 5 serious adverse events reported during the trials; none were considered related to the study vaccine. In contrast to the preclinical data, immune responses in humans were limited. Only low levels of binding antibodies and T-cell responses were seen at the highest doses. This trial also highlighted the difficulties in developing a novel vector for HIV.
Trial registration: ClinicalTrials.gov NCT00063778 NCT00097838.
Figures
Fig 1
Virus-like replicon particle vaccine and packaging system.
Fig 2
Maximum local (A) and systemic (B) reactogenicity following each dose (1, 2, or 3) at each dose level.
Fig 3
ELISA responses 2 weeks after 3rd vaccination (day 98). A solid dot represents a positive response, and an open dot is for a negative response. Numbers at the top show the number of responders/number of assay results and the percentage with a positive result. For each box plot, 25% of the data points lie below the box and 25% lie above the box, and the horizontal line inside the box is the median. The vertical lines (whiskers) above and below the box extend to the most extreme data point, which is no more than 1.5 times the height of the box.
Fig 4
51Cr release. The left panel shows CD4 responses 2 weeks after 3rd vaccination (day 98), presented as the percentage of specific lysis after CD8 depletion. The right panel shows the CD8 responses at the same time point, presented as the percentage of specific lysis after CD4 depletion. A solid dot represents a positive response, and an open dot represents a negative response. Numbers at the top show the number of responders/number of assay results. For each box plot, 25% of the data points lie below the box and 25% lie above the box, and the and the horizontal line inside the box is the median. The vertical lines (whiskers) above and below the box extend to the most extreme data point, which is no more than 1.5 times the height of the box.
Fig 5
ELISpot 2 weeks after 3rd vaccination (day 98). Data were obtained only for U.S. participants in study HVTN 059. A solid dot represents a positive response, and an open dot represents a negative response. Numbers at the top show the number of responders/number of assay results and the percentage with a positive result. For each box plot, 25% of the data points lie below the box and 25% lie above the box, and the horizontal line inside the box is the median. The vertical lines (whiskers) above and below the box extend to the most extreme data point, which is no more than 1.5 times the height of the box.
Fig 6
ICS 2 weeks after 3rd vaccination (day 98). Data were obtained only for U.S. participants in study HVTN 059. A solid dot represents a positive response, and an open dot represents a negative response. Numbers at the top show the number of responders/number of assay results and the percentage with a positive result. For each box plot, 25% of the data points lie below the box and 25% lie above the box, and the horizontal line inside the box is the median. The vertical lines (whiskers) above and below the box extend to the most extreme data point, which is no more than 1.5 times the height of the box.
Similar articles
- Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona-Fiol T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo J. Jaoko W, et al. PLoS One. 2010 Sep 21;5(9):e12873. doi: 10.1371/journal.pone.0012873. PLoS One. 2010. PMID: 20877623 Free PMC article. Clinical Trial. - First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team. Nyombayire J, et al. J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17. J Infect Dis. 2017. PMID: 28077588 Free PMC article. Clinical Trial. - A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
Omosa-Manyonyi G, Mpendo J, Ruzagira E, Kilembe W, Chomba E, Roman F, Bourguignon P, Koutsoukos M, Collard A, Voss G, Laufer D, Stevens G, Hayes P, Clark L, Cormier E, Dally L, Barin B, Ackland J, Syvertsen K, Zachariah D, Anas K, Sayeed E, Lombardo A, Gilmour J, Cox J, Fast P, Priddy F. Omosa-Manyonyi G, et al. PLoS One. 2015 May 11;10(5):e0125954. doi: 10.1371/journal.pone.0125954. eCollection 2015. PLoS One. 2015. PMID: 25961283 Free PMC article. Clinical Trial. - Killed whole-HIV vaccine; employing a well established strategy for antiviral vaccines.
Kang CY, Gao Y. Kang CY, et al. AIDS Res Ther. 2017 Sep 12;14(1):47. doi: 10.1186/s12981-017-0176-5. AIDS Res Ther. 2017. PMID: 28893272 Free PMC article. Review. - A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
Zolla-Pazner S, Michael NL, Kim JH. Zolla-Pazner S, et al. Lancet HIV. 2021 Jul;8(7):e449-e452. doi: 10.1016/S2352-3018(21)00073-4. Epub 2021 May 21. Lancet HIV. 2021. PMID: 34029515 Free PMC article. Review.
Cited by
- Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo.
Hick TAH, Geertsema C, Nguyen W, Bishop CR, van Oosten L, Abbo SR, Dumenil T, van Kuppeveld FJM, Langereis MA, Rawle DJ, Tang B, Yan K, van Oers MM, Suhrbier A, Pijlman GP. Hick TAH, et al. Mol Ther. 2024 Aug 7;32(8):2519-2534. doi: 10.1016/j.ymthe.2024.06.019. Epub 2024 Jun 17. Mol Ther. 2024. PMID: 38894543 Free PMC article. - Precise Therapy Using the Selective Endogenous Encapsidation for Cellular Delivery Vector System.
Tatarūnas V, Čiapienė I, Giedraitienė A. Tatarūnas V, et al. Pharmaceutics. 2024 Feb 19;16(2):292. doi: 10.3390/pharmaceutics16020292. Pharmaceutics. 2024. PMID: 38399346 Free PMC article. Review. - Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses.
Liu Y, Li Y, Hu Q. Liu Y, et al. Vaccines (Basel). 2023 Jun 24;11(7):1142. doi: 10.3390/vaccines11071142. Vaccines (Basel). 2023. PMID: 37514957 Free PMC article. Review. - The Delivery of mRNA Vaccines for Therapeutics.
Nitika, Wei J, Hui AM. Nitika, et al. Life (Basel). 2022 Aug 17;12(8):1254. doi: 10.3390/life12081254. Life (Basel). 2022. PMID: 36013433 Free PMC article. Review. - Next generation self-replicating RNA vectors for vaccines and immunotherapies.
Aliahmad P, Miyake-Stoner SJ, Geall AJ, Wang NS. Aliahmad P, et al. Cancer Gene Ther. 2023 Jun;30(6):785-793. doi: 10.1038/s41417-022-00435-8. Epub 2022 Feb 22. Cancer Gene Ther. 2023. PMID: 35194198 Free PMC article. Review.
References
- Agresti A, Coull BA. 1998. Approximate is better than “exact” for interval estimation of binomial proportions. Am. Stat. 52:199–256
- AlphaVax, Inc 2004. AVX101 clinical investigators brochure. AlphaVax, Inc., Research Triangle Park, NC
- Balasuriya UB, et al. 2002. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20:1609–1617 - PubMed
- Balasuriya UB, et al. 2000. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J. Virol. 74:10623–10630 - PMC - PubMed
- Bernstein DI, et al. 2009. Randomized, double-blind, phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484–493 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI048023/AI/NIAID NIH HHS/United States
- 5-U01-AI-46747/AI/NIAID NIH HHS/United States
- UM1 AI068614/AI/NIAID NIH HHS/United States
- 5-U01-AI-47976/AI/NIAID NIH HHS/United States
- 5-U01-AI-47980/AI/NIAID NIH HHS/United States
- U01 AI046747/AI/NIAID NIH HHS/United States
- U01 AI047980/AI/NIAID NIH HHS/United States
- 5-U01-AI-48013/AI/NIAID NIH HHS/United States
- U01 AI046703/AI/NIAID NIH HHS/United States
- 5-U01-AI-47985/AI/NIAID NIH HHS/United States
- U01 AI047985/AI/NIAID NIH HHS/United States
- UM1 AI068635/AI/NIAID NIH HHS/United States
- 3U01 AIO46747/PHS HHS/United States
- 5 U01 AI550771-02/AI/NIAID NIH HHS/United States
- U01 AI047976/AI/NIAID NIH HHS/United States
- N01AI30029/AI/NIAID NIH HHS/United States
- U01 AI048013/AI/NIAID NIH HHS/United States
- 5-U01-AI-48023/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous